The future of weight loss is fast approaching. At a recent scientific conference, drug companies showed off a variety of next-generation drugs for both obesity and type 2 diabetes. Some of these treatments might help people lose even more weight than current forerunners like Novo Nordisk’s semaglutide—the active…
It’s hard to go a day without hearing something new about the latest diabetes and obesity medications, semaglutide and tirzepatide. Usually, the buzz is positive, but there has been a persistent claim made about these drugs that would make any potential user wary: They don’t only help you lose weight—they supposedly…
This week, science reporter Isaac Schultz described a groundbreaking effort to measure the spin of a supermassive black hole, and a fascinating experimental archaeology experiment in which marines fought each otherto test how well ancient Mycenean armor works. Other science coverage included a botched SpaceX engine…
New research this month is the latest to link the use of Ozempic, Wegovy, and other GLP-1 drugs to a greater risk of gastroparesis, a potentially serious medical condition. So what exactly is gastroparesis and how worried should you be about it if you’re on or thinking about taking these medications?
The millennial-skewed telehealth platform Hims & Hers announced Monday that is now offering customers a compounded version of semaglutide, the active ingredient in popular weight loss drugs like Ozempic and Wegovy.
Results from the longest-running trial of semaglutide—the active ingredient in the popular drugs Ozempic and Wegovy—are in, and the verdict is decidedly positive. The study found that people taking semaglutide tended to maintain their initial weight loss for up to four years. Other trial data presented this week also…
Senator Bernie Sanders (I-VT) is taking aim at one of Big Pharma’s newest cash cows: the latest generation of effective obesity medications.
The results of a nine-month investigation by health regulators in the European Union should be comforting for anyone taking Ozempic and other similar drugs to treat type 2 diabetes and/or obesity. EU officials said Friday that they failed to find evidence of a causative link between GLP-1 drugs and an increased risk…
